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with depot and oral antipsychotics, respectively. 25 patients were
not treated with any antipsychotic medication, so were excluded
from the analyses. Compared with oral users, depot patients
were more likely to: have had more previous episodes of schiz-
ophrenia; have spent more days in hospital, be male; be less 
educated; be unemployed; be violent; and have experienced non-
violent crimes. Approximately 50% of all depot users were
treated with an oral antipsychotic supplement as co-therapy. A
higher proportion of depot users were admitted and re-admitted
to hospital throughout the study, with signiﬁcant differences in
year 2 and 3 (p < 0.01, respectively). The ALoS was consistently
higher in depot users compared with oral users over the three
years. CONCLUSION: Patients treated with typical depot
antipsychotics appear to be distinctly different from those treated
with oral antipsychotics. Depot users were found to consume
considerably more health care resources. This study indicates
that there may be a subset of the schizophrenia population whose
clinical needs are not currently well met by existing treatment
options.
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OBJECTIVE: The National Institute for Clinical Excellence’s
(NICE) initial evaluation of cholinesterase inhibitors for
Alzheimer’s disease failed to account for current guidance in the
UK, which states that only patients who respond to treatment
should continue with therapy. This study re-valuates cost-effec-
tiveness estimates using the same model in accordance with
current guidance. METHODS: The Assessment of Health Eco-
nomics in Alzheimer’s Disease (AHEAD) model, published in
2001, was adapted by the NICE appraisal group for their eval-
uation. The original AHEAD model was used to estimate the
cost-effectiveness of continuing therapy only in responders.
Where possible, model inputs were based on values used by
NICE. Only patients who experienced no decline in cognition
after six months of treatment with galantamine continued treat-
ment, for the subsequent ﬁve years. A health care payer per-
spective was adopted. Sensitivity analyses on costs, utilities,
discount rates, treatment effects and time horizon were con-
ducted. RESULTS: NICE reported the cost-effectiveness of
galantamine as £46,000 per discounted QALY gained in its aug-
mented base case results. Shadowing NICE inputs, and assum-
ing all patients continue with treatment regardless of response,
the original AHEAD model results in a ratio £32,000, so some
differences between the two analyses remain even when using
similar inputs. Using AHEAD, if only responders continue with
treatment, the ratio falls to £11,000, a 67% drop. If a respon-
der analysis in the NICE study would also result in a 67% reduc-
tion in their estimate, one would expect a new NICE ratio of
roughly £15,000. Treatment costs and time horizon were inﬂu-
ential. If projections are extended to 6 years, the ratio falls to
£7000. Varying the daily cost of galantamine by £0.50 changes
cost per QALY estimates by about £5000. CONCLUSIONS:
NICE’s initial cost-effectiveness assessment was not in agreement
with current guidance and results in inappropriately high esti-
mates of cost-effectiveness.
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OBJECTIVES: To compare 6-month medical costs and hospi-
talization risk of adults diagnosed with attention-deﬁcit/
hyperactivity disorder (ADHD) receiving extended-release
methylphenidate (OROS-MPH, CONCERTA®) to those receiv-
ing mixed amphetamine salts extended release (MAS-XR, 
Adderall XR®) or atomoxetine (Strattera®) from employer per-
spective. METHODS: We examined data from a U.S. employer
claims database of 5 million beneﬁciaries (1999–2004). Analysis
was restricted to adults aged 18–64 with at least one diagnosis
of ADHD (ICD-9: 314.x) and at least one prescription of OROS-
MPH, MAS-XR, or atomoxetine. Adults were required to have
continuous eligibility 6 months before and after their latest
therapy initiation and have no ADHD therapy in the prior 6
months. Descriptive measures of medical costs (including out-
patient and inpatient costs) and hospitalization risk were com-
puted over 6 months following therapy initiation. Generalized
estimating equations (GEE) models were used to compare costs
of adults receiving alternative therapies adjusting for baseline
demographic characteristics, substance abuse, depression, and
the Charlson comorbidity index. Costs were adjusted to 2004
dollars using medical CPI. RESULTS: Of the research sample (n
= 4569), 31.8% received OROS-MPH, 34.0% MAS-XR, and
34.2% atomoxetine. In the 6-month follow-up period, medical
costs were $1251 for OROS-MPH, $1422 for MAS-XR, and
$1581 for atomoxetine-treated adults. The GEE model adjust-
ing for patient characteristics found that 6-month medical costs
for OROS-MPH-treated adults were $141 less than for the MAS-
XR-treated (p = 0.02) and $132 less than for the atomoxetine-
treated (p = 0.03). The risk of having at least one hospitalization
was 42% higher for adults treated with MAS-XR (OR = 1.42,
95% CI: 0.99–2.05) and 51% higher for adults treated with ato-
moxetine (OR = 1.51, 95% CI: 1.05–2.17) compared to adults
treated with OROS-MPH. CONCLUSIONS: Over the 6-month
period after therapy initiation, adults treated with OROS-MPH
had lower medical costs than those treated with MAS-XR and
lower medical costs and risk of hospitalization than adults
treated with atomoxetine.
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OBJECTIVE: This analysis evaluated the medical cost savings of
delaying time to dialysis in elderly CKD patients receiving EPO.
METHODS: Using health claims and laboratory data from >35
health plans between January 1999 and April 2004, dialysis
patients (≥65 years) who had ≥1 hemoglobin (Hb) value and ≥1
glomerular ﬁltration rate (GFR) value <60mL/min prior to dial-
ysis were identiﬁed. Patients were excluded if they had an organ
transplant, had received blood transfusions or darbepoetin alfa,
or had received dialysis for non-CKD reasons. Each CKD patient
